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Summary The immunostimulatory capacities of B7.1-and B7.2- expressing melanoma cells were investigated. A365, 960306 and 950504
melanomas, established from nodular melanoma lesions, were retrovirally transduced. Irradiated B7-, B7.1+ and B7.2+ melanoma cells were
co-cultured with autologous or allogeneic peripheral blood mononuclear cells (PBMCs). Proliferation was assessed by [3H]thymidine uptake.
mRNA encoding for interleukin 2 (IL-2), IL-4, IL-10 and interferon gamma (IFN-y) was determined. IFN-y, IL-2, IL-4 and IL-10 secretion were
quantitated by ELISA. B7.1+ and B7.2+ melanomas induced proliferation of PBMCs and mRNA for IL-2 and IFN-'y. After co-incubation of
transduced melanoma cells with PBMCs, high levels of IL-10 were detectable in the supernatant. The presence of neutralizing anti-IL-10
antibodies resulted in enhanced proliferation and IL-2 and IFN-ysecretion. Our data indicate that B7.1- and B7.2-transduced melanoma cells
trigger lymphocytic proliferation with transcription of IL-10, IL-2 and IFN-y. Blocking of IL-10 augments these effects. Gene therapy protocols
using tumour cells as a vaccine have to consider the adverse effects of IL-10.
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Melanoma is an antigenic tumour (Bystryn, 1989). Several
proteins have been identified that are presented as peptides in the
grove of the HLA-I complex. These proteins include members of
the MAGE family (Zakut et al, 1993), gp 100 (Bakker et al, 1994)
or tyrosinase (Kawakami et al, 1994).
Although melanoma presents various specific antigens associ-
ated with HLA-I, it does not induce an immune response, which
results in an elimination ofthe malignant cells. It is speculated that
melanoma cells induce tolerance instead of activation by
presenting antigens without the respective co-stimulatory signals
(Becker et al, 1993a). These co-stimulatory signals can be
provided by B7.1 (CD80) or B7.2 (CD86), two molecules capable
of delivering co-stimulatory signals to T cells via CD 28 (Becker
et al, 1993a; Freeman et al, 1991, 1993; Guinan et al, 1994).
Thus, the immunogenicity of tumour cells is increased if the
cells are transfected with human B7.1 (Dohring et al, 1994).
Expression ofthe co-stimulatory ligand B7 on melanoma cells has
been shown to induce the rejection ofa murine melanoma in vivo
(Townsend and Allison, 1993). In addition, treatment of mice
bearing an 8-day established melanoma by intraperitoneal injec-
tion of B7+ tumour cells resulted in complete tumour regression
and cure (Li et al, 1994). In human melanomas, B7.1 expression
was found only in regressing lesions (Denfeld et al, 1995).
Consequently, there are human gene therapy protocols for
melanoma that apply melanoma cells genetically engineered to
express B7.1 (Fenton et al, 1995).
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We analysed the immunostimulatory potential of a B7.1- and
B7.2-transduced human melanomacell line. We showed that B7.1-
and B7.2-transduced melanoma cells induced proliferation and
expression of IL-2 and IFN-y. In addition, we demonstrated that
B7.2-transduced melanoma cells induced IL-4, and that the
presence ofIL-1O suppressed the response ofPBMCs.
MATERIALS AND METHODS
Cell culture: melanoma cells and peripheral blood
mononuclear cells (PBMCs)
Human PBMCs were obtained fromhealthy volunteers ormelanoma
patients after informed consent, and were separated by Ficoll-
Hypaque gradient centrifugation. After separation, the cells were
washed twice and immediately resuspended in complete medium
(CM) consistingofRPMI 1640(Gibco/BRL), Eggenstein, Germany)
supplemented with 10% of fetal bovine serum (FBS) (Gibco/BRL),
2 mM L-glutamine (Seromed, Berlin, Germany), 10mM sodium
pyruvate (Seromed), 100 U ml-1 penicillin (Seromed), 100mg ml-1
streptomycin (Seromed) and 50mg of gentamycin (Seromed).
Before proliferation experiments, lymphocytes were enriched by
plastic adherence over night and collection ofthe non-adherent cells.
The melanoma cell line A365 (kindly provided by U Reinhold,
Department ofDermatology, Bonn, Germany) was also cultured in
CM. The 950504 melanoma cells were established from a primary
nodular melanoma of a 27-year-old female patient, the 960306
from a skin metastasis of a 36-year-old man as described earlier
(Becker et al, 1993b). Both melanomas expressed human HLA
class I, as determined by flow cytometry with the MAb W6/32,
and ICAM-1, as determined with the MAb 8.4A6, but they were
negative for HLA-DR (data not shown).
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Table 1 Allogeneic PBMCs were stimulated with A365 melanoma cells that were either untransfected (wt) ortransfected with B7.1+ or B7.2. After 2 days of
incubation, mRNA was extracted, reverse transcribed and the cDNA amplified with specific primers. PCR products were detected by PCR-ELISA
OD ± s.d. (405-492 nm)
Samples IL-2 IL-4 IL-10 IFN-y 3-Actin
A365wt 0.083 ± 0.007 0.094 ± 0.008 2.497 ± 0.192 0.048 ± 0.003 0.932 ± 0.078
A365B7.1 0.948 ± 0.087 0.105 ± 0.012 2.463 ± 0.213 0.434 ± 0.031 0.909 ± 0.084
A365B7.2 0.834 ± 0.076 0.394 ± 0.024 1.055 ± 0.147 0.297 ± 0.019 1.001 ± 0.109
Positive control 1.001 ±0.098 1.028± 0.094 1.618± 0.151 1.006± 0.021 1.008± 0.099
Negative control 0.068 ± 0.005 0.055 ± 0.004 0.074 ± 0.006 0.053 ± 0.003 0.056 ± 0.004
Figure 1 A365 melanoma cells transduced with viral supernatants containing human B7.1 or B7.2 cDNA were stained with anti-CD80-FITC MAb, with anti-
CD86-FITC MAb or with saturating concentrations of anti-human CTLA4-lgG fusion protein, followed by FITC-conjugated goat anti-human IgG Ab. Samples
were analysed by flow cytometry, the histograms show log fluorescence vs number of cells
Construction of B7.1 and B7.2 retroviral vectors
The B7.1 and B7.2 open reading frames were amplified from
Epstein-Barr virus B-cell cDNA (Dohring et al, 1994).
Amplification was carried out on a DNA Thermal Cycler (Perkin-
Elmer Cetus) using the following conditions: 94°C, 1 min, then
25 cycles of94°C, 15 s, 60°C, 30 s, 72°C, 45 s, followed by 72°C,
10 min. The amplified PCR product was cloned into the retroviral
vector pLXSN (Miller and Rosman, 1989). The sequence of the
B7 inserts was verified to be identical to the published sequence
(Freeman et al, 1991, 1993) (data not shown). Bacteria were trans-
formed by electroporation, selected on ampicillin-containing agar
plates, and plasmid DNA fromresistant colonies was purified. The
retroviral constructs were packaged in an ecotropic packaging
system using the GP+E cell line. Amphotropic packaging was
performed using the cell line GP+envAM12 (Markowitz et al,
1988). As determined by infection on NIH3T3 cell layers, the titre
of the viral supematants was in excess of 106 ml-1. These super-
natants were used to transduce the A365 and 950504 melanoma
cells with B7.1 or B7.2. After 2 days, 1 mg ml-l G418
(Gibco/BRL) was added to the culture forthe selection ofresistant
cells (Dohring et al, 1994).
Proliferation assays
B7.1+, B7.2+, mock-transfected and B7- A365 melanoma cells
were tested for their capacity to stimulate allogeneic T cells. As
there was no difference between mock-transfected and wt A365
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Figure 2 Untransduced A365, A365-B7.1+ orA365-B7.2+ cells (2 x 104 cells
per well irradiated for 60 s) incubated with resting allogenic PBMCs for 0.5, 2,
4, 6, 8, 10 days. Thereafter, the cultures were labelled for 18 h with
[3H1thymidine, and the radioactivity incorporated was assessed by liquid
scintillation counting (c.p.m. mean ± s.e.m., n = 3, s.e.m. < 200 c.p.m. not
shown). A good discrimination between transduced and wt cell stimulation
was already possible after 2 days
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Figure 3 RT-PCR for IL-2 and IFN-yin allogenic PBMCs stimulated by B7-
A365, A365-B7.1 + or A365-B7.2+ cells. The beta-actin control extinction after
hybrdization is shown in Table 1
Table 2 Cytokine secretion of autologous and allogeneic PBMCs stimulated
with B7-, B7.1+ or B7.2+ transduced melanoma cells
Cells IL-2 IL-4 IL-10 IFN-y
Autologous
M960306wt 0 0 355.0 0
M960306B7.1 3.9 0.6 167.1 10.1
M960306B7.2 8.8 2.1 109.1 22.0
Allogeneic
M960306wt 0 0 270.0 0
M960306B7.1 8.5 0 278.0 84.0
M960306B7.2 3.5 0.5 280.0 13.4
(data not shown), only wt cells were used as control. PBMCs were
cultured with irradiated stimulator cells in 96-well flat-bottomed
microtitre plates in 200 jl of RPMI-5% human serum. In some
experiments, PBMCs were cultured with 104 irradiated tumour
cells in U-bottomed microtitre plates. After 2-3 days (or later if
indicated), the cultures were labelled with [3H]thymidine, and the
radioactivity incorporated was assessed by liquid scintillation
counting. The identical approach was used to analyse the prolifer-
ation induced by untransduced and B7.1+ 950504 melanoma cells
co-cultured with autologous PBMCs.
For mRNA extraction 3 x 106 PBMCs were coincubated with
3 x 105 irradiated melanoma cells in six-well flat-bottomed plates
for 2 days. Supematants for cytokine measurements and PBMCs
for mRNA extraction were harvested on day 2.
Flow cytometric analysis
The following primary MAbs were used at the concentrations indi-
cated: W6.32 (supernatant purified on protein G sepharose; mouse
IgG2a) reacting with a monomorphic determinant on the human
HLA class I A, B, C molecules (Brodsky and Parham, 1982;
3.6gg ml-'); L243 (Becton Dickinson, San Jose, CA, USA; mouse
IgG2a)recognizing human HLA class II DRepitopes (Robbins etal,
1987; 2.5 jg ml-'); 8.4A6 (Ancell, Bayport, MN, USA; mouse
IgGl) recognizing D2 domain ofthe human CD54 (ICAM-1) mole-
cule (Reilly et al, 1995; 5.0jg ml-'). MAB104 (Immunotech,
Marseille, France; mouse IgGI) reacting with B7.1 co-stimulatory
molecule (Valle et al, 1990; 20 jg ml-'); and BU63 (Ancell; mouse
IgGI) reacting with B7.2co-stimulatorymoleculq (Caux etal, 1994;
4.2 jg ml-'). The hCTLA4-IgG fusion protein, consisting ofhuman
CTLA4 extracellular domain and human IgGI constant domains,
binds to both B7.1 and B7.2 molecules with even higher affinity
than CD28, the natural ligand for these receptors (supematant puri-
fied on protein G sepharose; Dohring etal, 1994; 2.0jg ml-').
Adherent cells were detached with a solution containing 0.05%
trypsin and 0.02% EDTA (Seromed), inactivated with fresh media
and washed once with F-PBS [phosphate-buffered saline without
Ca++/Mg++ containing 1% fetal calf serum (FCS)] and 0.2 mg ml-'
sodium azide. Approximately 5-10 x 105 cells each were incu-
bated with different MAbs at concentrations indicated above in a
total volume of 200 jl for 45 min on ice in the dark. After
washing, non-conjugated antibodies were stained with 1:30 dilu-
tion (in F-PBS) of either FITC-conjugated rabbit anti-mouse or
anti-human IgG secondary antibody (Dako, Glostrup, Denmark)
for 30 min on ice in the dark. In all cases, cells were also stained
with the appropriate isotype-matched control antibodies, non-
specific mouse IgGl or IgG2a (Becton Dickinson). After washing
and fixation with 0.5% formaldehyde in F-PBS, fluorescence of
the cells was measured by an Epics Profile II cytofluorometer
(Coulter, Miami, FL, USA). Non-viable cells were gated out.
FACS data are presented as log offluorescence intensity vs counts.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
RNA extraction from PBMCs ormelanomacells was performed as
follows: the cell pellet was taken up in buffer A (10 mm Hepes,
10 mm potassium chloride, 1 mm EDTA, 1 mm EGTA) and lysed
by vortexing with the addition of 1:16 vol. of 10% NP40. The
supernatant was added to an equal volume ofbuffer B (7 M urea,
1% sodium dodecyl sulphate, 0.35 M sodium chloride). After one
phenol-chloroform extraction and one chloroform extraction the
RNA was precipitated with ethanol-glycogen and dissolved in
DEPC-water. The RNA was quantified by reading absorbance at
260 nm (A260); 2-4 jg of RNA were used to synthesize cDNA
(M-MuLV reverse transcriptase from New England Biolabs).
PCR analysis
PCR was performed with the incubation buffer supplied with the
Taq DNA polymerase (Boehringer, Mannheim, Germany), with
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PCR DIG labelling nucleotide mix (Boehringer) and with 2.0 ,UM
oligonucleotide primers. All cDNAs were first amplified with
primers forbeta-actin to test the quality and quantity ofthe cDNA.
Only satisfactory cDNA was then subjected to PCR with primers
for IL-2, IL-4, IL-10 and IFN-y. Primers were selected using the
Oligo Primer Analysis Software program version 4.0 (National
Biosciences), except for primers for IL-10, which have published
sequences: upper primer pos. 323, 27 nt (Vieira et al, 1991); lower
primer pos. 646, 27 nt (Butch et al, 1993). Primer sequences were
sent to genebank to exclude cross-binding to other published
sequences (Altschul et al; 1990) and were published recently
(Dummer et al, 1996). PCR was performed with Perkin Elmer
9600 GenAmp cyclers. Annealing temperatures were 55°C for
IFN-y, IL-2 and IL-12p35; 62°C for IL-4, IL-5, IL-7 and IL12p40;
and 66°C for IL-10 and IL-13. One cycle (93°C, 2 min 30 s,
annealing temperature 1 min 30 s, 72°C, 1 min 30 s) was followed
by 30 cycles (94°C, 30 s, annealing temperature, 30 s, 72°C, 1 min
30 s). An aliquot of PCR product was electrophoresed on a 1.6%
agarose gel and visualized by ethidium bromide staining. In all
PCR reactions, positive controls from various cell lines (see Table
1) and water as negative control were included.
Cytokine ELISA
Using commercially available ELISAs, the supematants of
PBMCs were screened for the cytokines IFN-y, IL-2, IL-4, IL-1O;
after co-incubation with melanoma cells (ELISAs obtained from
R&D Systems, Minneapolis, MN, USA).
RESULTS
Transduced melanoma cells express B7.1 or B7.2
Human A365 cells were stably transduced with viral supernatants
containing human B7.1 or human B7.2 cDNA. 950504 melanoma
cells were transduced with B7.1 only. Transduced cells were
strongly stained with anti-CD80-FITC MAb, anti-CD86-FITC
MAb or with saturating amounts of human CTLA4-IgG fusion
protein, followed by FITC-conjugated goat anti-human IgG. Flow
cytometric analysis revealed high levels of human CTLA4-IgG
binding to both B7.1- and B7.2-transduced A365 or 950504
melanoma cells. Figure 1 shows the cytometric analysis of B7.1-
and B7.2-positive A365 and A365 wt.
PCR ELISA
For the PCR enzyme-linked immunosorbent assay (ELISA),
nucleotide probes were selected with the Oligo software for the
sequences of the cDNA fragment amplified (see Table 1) by the
specific primers and obtained biotinylated (Microsynth, Balgach,
Switzerland). The specifity of all PCR products was confirmed
with this method. PCR ELISA was performed according to kit
directions (Boehringer). Hybridization was specific at 45'C for all
probes except for IL-10. To exclude non-specific binding,
hybridization with the IL-10 probes was performed at 50°C. The
specific capture probe/PCR product hybrids were boundto strepta-
vidin-coated microtitre plates via the biotin label of the probes.
After washing, the immobilized hybrids were treated with anti-
DIG peroxidase-conjugated antibody and ABTS, a substrate for
the peroxidase. The plates were measured by reading A492 and
values that were higher than 2x the reading of the PCR reaction
mix with water instead ofcDNA werejudged to be positive for the







A365 and 950504 melanoma cells express IL-10
Using the RT-PCR ELISA technique, we detected mRNA
encoding for IL-10 in A365 and 950504 melanoma cells (Dummer
and Boni, 1995). A365 cells were also positive for IL-5 and IL-7,
but not for IL-2, IL-4, IL-12p35/40, IL-13 or IFN-y, as determined
by RT-PCR ELISA (data not shown). The presence of anti-IL-10
Ab did not affect the expression of B7.1/B7.2 molecules on the
surface ofmelanoma cells (data not shown).
B7.1+ and B7.2+ melanoma cells induce proliferation of
PBMCs
After irradiation, the B7.1- and B7.2-transduced cells induced a
significantly higher proliferative response than untransduced cells
or A365 cells transduced with empty vector, when autologous or

















Figure 4 Melanoma-induced proliferation of PBMCs in an allogeneic
system after neutralization of IL-10 by an anti-IL-10 Ab. Neutralization of






Figure 5 Determination of melanoma-induced proliferation of PBMCs in an
autologous system after neutralization of IL-10 by an anti-IL-10 Ab.
Neutralization of IL-10 results in a doubling of the proliferation (c.p.m.
mean ± s.e.m., n =3)
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Table 3 Comparison of cytokine levels after co-incubation of irradiated melanoma cells with allogeneic PBMCs after 2 days in the presence of 10 9g of a
neutralizing anti-IL-10 Ab or a control Ab (10 jig of a neutralizing anti-IL-7 Ab
Stimulators MAb IFN-y(48 h) IL-2 (48 h) IL-4(48 h)A IL-10(48 h)
A365 wt Control 1.8/1.9 0/0 0/0 204.5/881.3
A365wt Anti-IL 10 Ab 2.6/3.8 0/0.5 0/0 0.1/121.8
A365B7.1 Control 9.2/48.5 0/0.61 0/0.8 2023.4/2973.8
A365B7.1 Anti-IL 10 Ab 27.6/251.6 93.5/104.5 0/0.2 2.4/57.5
A365B7.2 Control 6.1/43.3 0/8.73 0/7.2 1997.7/1271.1
A365B7.2 Anti-IL 10 Ab 17.8/256.1 66.6/11.1 0.1/0 0.9/310.0
All values are indicated in pg ml-'. PBMCs and melanoma cells alone did not secret measurable amounts of the cytokines listed. Shown are the values of
experiment 1 / experiment 2 (two different donors of the PBMCs).
B7.1-positive cells mixed together with A365 B7.2-positive cells
did not produce a stronger proliferative response than A365-B7.1+
or A365-B7.2+ cells alone (data not shown).
A365-B7.1+ and -B7.2+ melanoma cells induce mRNA for
IL-2, IL-10 and IFN-y, only A365-B7.2+ cells induce IL-4
mRNA in PBMCs
A365 cells transduced with B7.1 or B7.2 induce mRNA for the
lymphokines IL-2 and IFN-yin PBMC (Figure 3). The specifity of
all PCR products were confirmed by ELISA reactions after
hybridization ofbiotinylated probes (results are shown in Table 1).
These cytokines and IL-10 were present in the supernatants of
autologous or allogeneic PBMCs with A365 and 960306
melanoma cells (Tables 2 and 3). Mock-transfected and wt A 365
did not induce IL-2 secretion (data not shown). A365 cells trans-
duced with B7.2 induced PBMCs to transcribe and secrete IL-4 in
addition to IL-2 and IFN-y.
Neutralizing anti-IL-10 Ab enhances B7.1+ and B7.2+
melanoma cells induced proliferation of PBMCs and
inhibits IL-10 secretion
The addition of 10 ig of polyclonal neutralizing antibody against
human IL-10 or against IL-7 as control (both antibodies from
R&D Systems) enhanced the proliferative response induced by
B7.1+ and B7.2+ melanoma cells in an autologous and allogeneic
system (Figure 4 and 5). Ten micrograms of an anti-IL-7 neutral-
izing Ab were used as a control. It did not affect proliferation.
Comparing the cytokine secretion in the presence ofanti-IL-lO Ab
with the control, we found an enhancement of IL-2 and IFN-y
secretion (Table 3).
IL-4 was only detected in significant amounts if PBMCs were
stimulated with B7.2+ melanoma cells without anti-IL-10 Ab
(Table 3).
DISCUSSION
The goal ofan effective vaccination therapy ofcancer is to induce a
specific anti-tumour response mediated by T cells eradicating the
disseminated neoplasm. In addition to antigen-specific signals medi-
ated by HLA-associated peptides that are delivered by the T-cell
receptor, co-stimulatory signals delivered by CD28 are necessary to
achieve a cytotoxic immune response that is also effective against
B7-negative tumour cells (D6hring et al, 1994; Guinan et al, 1994).
We have used a retroviral system to transduce B7.1 (Dohring et
al, 1994) and B7.2 into melanoma cells. After selection, more than
90% of the melanoma cells expressed the transgene. They were
used to characterize the immune response of allogeneic or autolo-
gous PBMCs after co-incubation of irradiated tumour cells to
mimic the in vivo situation during a vaccination therapy.
We confirmed that B7+ melanoma cells induce proliferation in
PBMCs (Sule-Suso et al, 1995). The maximum thymidine uptake
was already achieved after a 2-day co-incubation and continued
for 3-5 days. This proliferation is accompanied by the transcrip-
tion of IL-2 and IFN-y. Comparing B7.1+ and B7.2+ cells, there
were no significant differences regarding proliferation, IL-2 and
IFN-y in some experiments. Freeman and co-workers using CHO
cells transfected with B7.1 orB7.2 showed that B7.2 induced IL-4,
particularly in naive CD4+ CD45RA+ cells (Freeman et al, 1995).
In an experimental allergic encephalomyelitis model, blocking of
B7.1 by Ab resulted in a type 1 helper T-cell (THI) response and
blocking of B7.2 resulted in a TH2 response in vitro and in vivo
(Kuchroo et al, 1995). The explanation for this observation still
remains unclear as CD28 and CTLA-4 fusion proteins bind with
indistinguishable affinity to B7.1 and B7.2 respectively (Lanier
et al, 1995). However, CTLA-4 binding is of higher affinity to
both B7.1 and B7.2. In the clinical situation of a metastasizing
melanoma, a THI response would be preferred. Thus, B7.1
appears to bethe morepromising transgene than B7.2 forthe treat-
ment ofcancer (Gajewski et al, 1996).
The analysis of the cytokine spectrum displayed by melanoma
cells (Becker et al, 1994; Chen et al 1994; Mattei et al, 1994;
Dummer and Boni, 1995; Kruger-Krasagakes et al, 1995) revealed
that melanoma cells transcribe and secrete IL-10. IL-10 is a
cytokine with avariety ofeffects, including inhibition ofmonocyte
major histocompatibility complex (MHC) class II-dependent
antigen presentation, THI cytokine production and inhibition of
T-cell proliferation (Howard and O'Garra, 1992; deWaal Malefyt
et al, 1993; Becker et al, 1994). In addition, it protects target
cells from tumour- and allo-specific cytotoxic T cells and down-
regulates HLA class I expression (Matsuda et al, 1994).
In the supematants ofmelanomacells alone, we could not detect
IL-10 protein in contrast to the supematants of PBMCs coincu-
bated with melanoma cells, probably because of a limited sensi-
tivity of the applied ELISA assay. Therefore, we have to assume
that PBMCs and not the melanoma cells are the source for most of
the IL-10 found in the supernatants. By a yet undefined mecha-
nism, transduced as well as untransduced melanoma cells induce
this cytokine in PBMCs.
BritishJournal ofCancer(1998) 77(9), 1413-1419 0CancerResearch Campaign 19981418 R Dummer etal
We wondered whether the IL-1O has an impact on the
stimulatory potential of B7+ melanoma cells. The presence of a
neutralizing Ab against IL-10, but not against IL-7, resulted in a
considerable increase of the proliferation induced by the
melanoma cells using allogeneic as well as autologous melanoma
cells. Even more pronounced was the effect of IL-10 blockage on
IL-2 and IFN-y secretion, which was increased by at least a factor
of50. These data clearly suggest antagonizing effects of IL-IO.
We conclude that transduction of B7.1 into melanotic tumour
cells may not be sufficient to establish an efficient T-cell response
because of tumour cell-induced inhibitory factors, such as IL-10.
Future gene therapy protocols using B7.1+-transduced tumour
cells or tumour cells modified by other transgenes as vaccines
have to consider strategies to antagonize IL-10.
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